Skip to main content
Premium Trial:

Request an Annual Quote

Amersham Pharmacia Biotech Will Acquire Molecular Dynamics

Premium

SUNNYVALE, Calif.--Amer sham Pharmacia Biotech, the joint venture between Nycomed Amersham and Pharmacia & Upjohn, and its strategic partner here, Molecu lar Dynamics, entered into a merger agreement providing for the acquisition of Molecular Dynamics by Amer sham.

The companies claimed the acquisition will strengthen Amersham's competitive position in the market for DNA sequencing and genomic analysis. Under terms of the agreement, Amersham will initiate a cash tender offer of $20.50 per Molecular Dynamics share, thereby valuing the entire, fully diluted Molecular Dynamics' share capital at approximately $256 million.

The two companies formed a strategic alliance in 1994 that has brought together the molecular biology and chemistry skills of Amersham with the instrumentation and software capabilities of Molecular Dynamics to develop and market complete DNA sequencing and genomic analysis systems.

Filed under

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.